Methicillin-resistant staphylococcus aureus in Europe, 1999-2002

Emerging Infectious Diseases

Volumn 10, Issue 9, 2004, Pages 1627-1634

  Tiemersma, Edine W ^a   Bronzwaer, Stef L A M ^a   Lyytikäinen, Outi ^b   Degener, John E ^c   Schrijnemakers, Paul ^a   Bruinsma, Nienke ^a   Monen, Jos ^a   Witte, Wolfgang ^d   Grundmann, Hajo ^a   Mittermayer, H ^e   Koller, W ^e   Goossens, H ^e   Hendrickx, E ^e   Markova, B ^e   Kalenic, S ^e   Tambic Andrasevic, A ^e   Urbaskova, P ^e   Monnet, D ^e   Naaber, P ^e   Lyytikainen O ^e   Nissinen, A ^e   Aubry Damon, H ^e   Courvalin, P ^e   Buchholz, U ^e   Witte, W ^e   Legakis, N ^e   Vatopoulos, G ^e   Fuzi M ^e   O'Flanagan, D ^e   Murphy, O ^e   Kristinsson, K ^e   Raz, R ^e   Cornaglia, G ^e   D'Ancona, P ^e   Hemmer, R ^e   Borg, M ^e   De Neeling, A ^e   Tiemersma, E ^e   Hoiby, A ^e   Bjorlow E ^e   Hryniewicz, W ^e   Canica M ^e   Codita, I ^e   Gubina, M ^e   Kolman, J ^e   Langsadl, L ^e   Baquero, F ^e   Campos, J ^e   Liljequist, B ^e   Johnson, A ^e   Whale, M ^e   more..

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ROBERT KOCH INSTITUTE   (Germany)

^e Natl Inst for Pub Hlth/Environ ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BELGIUM; EUROPE; GEOGRAPHIC DISTRIBUTION; GERMANY; HOSPITAL; IRELAND; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NETHERLANDS; SEROPREVALENCE; SLOVENIA; UNITED KINGDOM;

EID: 4444271222     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1009.040069     Document Type: Article

References (43)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-32.
2. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7:327-32.
3. World Health Organization. WHO global strategy for containment of antimicrobial resistance. WHO/CDS/CSR/DRS/2001.2. Geneva: The Organization; 2001 [cited 21 Jan 2004]. Available from http://www.who.int/csr/resources/ publications/drugresist/EGlobal_Strat.pdf
4. Monnet DL. Toward multinational antimicrobial resistance surveillance systems in Europe. Int J Antimicrob Agents. 2000;15:91-101.
5. Goettsch W, Bronzwaer SLAM, De Neeling AJ, Wale MC, Aubry-Damon H, Olsson-Liljequist B, et al. Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). Clin Microbiol Infect. 2000;6:59-63.
6. Bronzwaer SL, Goettsch W, Olsson-Liljequist B, Wale MC, Vatopoulos AC, Sprenger MJ. European Antimicrobial Resistance Surveillance System (EARSS): objectives and organisation. Euro Surveill. 1999;4:41-4.
7. Veldhuijzen I, Bronzwaer SL, Degener J, Kool JL, European Antimicrobial Resistance Surveillance System Participants. European Antimicrobial Resistance Surveillance System (EARSS): susceptibility testing of invasive Staphylococcus aureus. Euro Surveill. 2000;5:34-6.
8. Tiemersma EW, Lyytikainen O, Bronzwaer S, Schrijnemakers P, Witte W, European Antimicrobial Resistance Surveillance System Participants. Geographical and time trends in proportion of methicillin resistant Staphylococcus aureus (MRSA) in Europe (1999-2001) reported through the European Antimicrobial Resistance Surveillance System (EARSS). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2000. Abstract C2-293, 2002. Washington: American Society for Microbiology; 2002.
9. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis. 1994;13:50-5.
10. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol. 2001;39:3727-32.
11. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis. 2000;30:454-60.
12. Cookson B. Aspects of the epidemiology of MRSA in Europe. Chemother J. 1995;7 (Suppl 3):93-8.
13. Grundmann H, Tami A, Hori S, Halwani M, Slack R. Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community. BMJ. 2002;324:1365-6.
14. Morgan M, Evans-Williams D, Salmon R, Hosein I, Looker DN, Howard A. The population impact of MRSA in a country: the national survey of MRSA in Wales, 1997. J Hosp Infect. 2000;44:227-39.
15. Scudeller L, Leoncini O, Boni S, Navarra A, Rezzani A, Verdirosi S, et al. MRSA carriage: the relationship between community and healthcare setting. A study in an Italian hospital. J Hosp Infect. 2000;46:222-9.
16. Wertheim HF, Vos MC, Boelens HA, Voss A, Vandenbroucke-Grauls CM, Meester MH, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect. 2004;56:321-5.
17. Abudu L, Blair I, Fraise A, Cheng KK. Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol Infect. 2001;126:351-6.
18. Bronzwaer S, Buchholz U, Courvalin P, Snell J, Cornaglia G, De Neeling A, et al. Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: an external quality assurance exercise of the European Anlimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS). J Antimicrob Chemother. 2002;50:953-64.
19. Leegaard TM, Caugant DA, Froholm LO, Hoiby EA. Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect. 2000;6:290-3.
20. Skov R, Smyth R, Clausen M, Larsen AR, Frimodt-Moller N, Olsson-Liljequist B, et al. Evaluation of a cefoxitin 30 μg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2003;52:204-7.
21. Austin DJ, Anderson RM. Transmission dynamics of epidemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in England and Wales. J Infect Dis. 1999;179:883-91.
22. Monnet DL, Lopez-Lozano JM, Campillos P, Burgos A, Yague A, Gonzalo N. Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models. Clin Microbiol Infect. 2001;7:S29-36.
23. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995. Infection. 1999;27(Suppl 2):S2-8.
24. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA, for the Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeits-prüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 2001. Bonn (Germany): Antiinfectives Intelligence; 2003 [cited 21 Jan 2004]. Available from: http://www. antiinfectives-intelligence.de/peg/ag_resistenz/main.htm
25. Speller DC, Johnson AP, James D, Marples RR, Charlett A, George RC. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet. 1997;350:323-5.
26. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ. 2000;320:213-6.
27. Birchard K. Ireland tackles antimicrobial resistance in hospitals. Lancet. 2001;357:2113.
28. Cunney R. SARl Update. EPI-INSIGHT of the National Disease Surveillance Centre 2002;3:4 [cited 16 Apr 2004]. Available from: http://www.ndsc.ie/ Publications/EPI-Insight/2002Issues/d517.pdf
29. Health Protection Agency-Communicable Disease Surveillance Centre. The first year of the Department of Health's mandatory MRSA bacteraemia surveillance scheme in acute NHS Trusts in England: April 2001-March 2002. CDR Weekly. 2002;12:1-17 [cited 21 Apr 2004]. Available from: http://www.hpa.org.uk/cdr/ PDFfiles/2002/cdr2502.pdf.
30. Department of Health. Mandatory bacteraemia surveillance scheme-MRSA bacteraemia by NHS Trust [cited 21 Apr 2004]. Available from: http://www.dh.gov.uk/assetRoot/04/06/39/46/04063946.pdf.
31. Department of Health. Winning ways. Working together to reduce healthcare associated infection in England. Report from the Chief Medical Officer. London: Crown Copyright; 2003 [cited 21 Apr 2004]. Available at http://www. publications.doh.gov.uk/cmo/hai/winningways.pdf.
32. Wannet W. Spread of an MRSA clone with heteroresistance to oxacillin in the Netherlands. Euro Surveill. 2002;7:73-4.
33. Witte W, Kresken M, Braulke C, Cuny C. Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals. Clin Microbiol Infect. 1997;3:414-22.
34. Melter O, Santos Sanches I, Schindler J, Aires de Sousa M, Mato R, Kovarova V, et al. Methicillin-resistant Staphylococcus aureus clonal types in the Czech Republic. J Clin Microbiol. 1999;37:2798-803.
35. Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE Jr, Gaynes RP, et al. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Infect Control Hosp Epidemiol. 1998;19:388-94.
36. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362-86.
37. McDonald P, Mitchell E, Johnson H, Rossney A, Humphreys H, Glynn G, et al. Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999. J Hosp Infect. 2003;54:130-4.
38. Kotilainen P, Routamaa M, Peltonen R, Oksi J, Rintala E, Meurman O, et al. Elimination of epidemic methicillin-resistant Staphylococcus aureus from a university hospital and district institutions, Finland. Emerg Infect Dis. 2003;9:169-75.
39. Harbarth S, Albrich W, Goldmann DA, Huebner J. Control of multiply resistant cocci: do international comparisons help? Lancet Infect Dis. 2001;1:251-61.
40. Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211-5.
41. Duckworth G. Controlling methicillin resistant Staphylococcus aureus. BMJ. 2003;327:1177-8.
42. Duckworth G, Cookson B, Humphreys H, Heathcock R. Revised methicillin-resistant Staphylococcus aureus infection control guidelines for hospitals. Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. J Hosp Infect. 1998;39:253-90.
43. MacKenzie FM. Inventory of antibiotic resistance and use patterns in European hospitals: first results from ARPAC. Clin Microbiol Infect. 2003;9:S19-130.